Trends in Pharmacological Sciences
TIPS reviewTherapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents
References (43)
- et al.
- et al.
J. Lipid Res.
(1989) - et al.
J. Lipid Res.
(1985) - et al.
J. Lipid Res.
(1987) - et al.
J. Lipid Res.
(1983) - et al.
J. Lipid Res.
(1984) - et al.
J. Lipid Res.
(1990) Biochem. Biophys. Res. Commun.
(1987)- et al.
Clin. Chim. Acta
(1986) - et al.
J. Atheroscler. Res.
(1967)
Jpn. J. Pharmacol.
J. Pharm. Sci.
Biochem. Pharmacol.
Atherosclerosis
New Engl. J. Med.
Am. J. Physiol.
Scand. J. Gastroenterol.
FASEB J.
Arteriosclerosis
Biochem. J.
Cited by (241)
Polypyrrole and enzyme free cholesterol flakes based composite: Selective determination of theophylline
2021, Journal of Pharmaceutical and Biomedical AnalysisSterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport syndrome
2020, Kidney InternationalHypolipidemic effect of dihydroisoquinoline oxaziridine in high-fat diet-fed rats
2016, Biomedicine and PharmacotherapyCitation Excerpt :Hyperlipidemia is a major risk factor that can facilitate the development of coronary artery disease and the progression of atherosclerotic lesions [30]. An increase in lipid profiles as a contributing factor to the pathogenesis of atherosclerosis and associated cardiac disorders has warranted increased focus on the development of novel and more effective anti hyperlipidemic agents [31,32]. Actually, the consumption of high-fat diets (HFDs) is a central risk factor for metabolic disorders linked to obesity [33].
Some molecular targets for antihyperlipidemic drug research
2014, European Journal of Medicinal ChemistryCitation Excerpt :In most cell types, CE are present only in low levels, mainly as cytoplasmic lipid droplets. In plasma, CE are part of the neutral lipid cargo present in the intestinal chylomicrons and in the hepatic VLDL [67]. In the atherosclerotic disorder, chronic accumulation of CE in macrophages causes these cells to appear foamy.
Macrophage cholesteryl ester mobilization and atherosclerosis
2010, Vascular Pharmacology